NCT05782894View on ClinicalTrials.gov

Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

November 25, 2023

Study Completion Date

November 25, 2023

Conditions
SedativeMechanical Ventilation
Interventions
DRUG

Remimazolam besylate

0\~2.0mg/kg/h

DRUG

Propofol

0.3\~4.0mg/kg/h

DRUG

Remifentanil

1.5\~12μg/kg/h

Trial Locations (1)

430022

Wuhan Union Hospital, Wuhan

All Listed Sponsors
collaborator

Yichang Humanwell Pharmaceutical Co., Ltd., China

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER